EFTA00130083¶
NMS Labs¶
Phone:¶
CONFIDENTIAL¶
e-mail:¶
PhD, F-ABFT, DABCC-TC, Laboratory Director¶
Toxicology Report¶
| Report Issued | 08/22/2019 | 17:09 |¶
| :--- | :--- | :--- |¶
| To: | 10074
New York Office of Chief Medical Examiner¶ Attn: Department of Toxicology¶ 520 First Avenue¶ New York, NY 10016 |
| Patient Name | FT19-03508 M19-019432 |
|---|---|
| Patient ID | NP |
| Chain | 19244749 |
| Age Not Given | DOB Not Given |
| Gender | Not Given |
| Workorder | 19244749 |
Page 1 of 2¶
Positive Findings:¶
| None Detected |
See Detailed Findings section for additional information¶
Testing Requested:¶
| Analysis Code | Description |
| 9560B | Synthetic Cannabinoids Screen(2019 Scope),Blood |
Specimens Received:¶
| ID | Tube/Container | Volume/Mass | Collection Date/Time | Matrix Source | Miscellaneous Information |
|---|---|---|---|---|---|
| 001 | Gray Top Tube | 4.25 mL | Not Given | Femoral Blood |
All sample volumes/weights are approximations. Specimens received on 08/14/2019.¶
NMS v.18.0¶
EFTA00130084¶
CONFIDENTIAL¶
| Workorder | 19244749 |
| Chain | 19244749 |
| Patient ID | NP |
Page 2 of 2¶
Detailed Findings:¶
Examination of the specimen(s) submitted did not reveal any positive findings of toxicological significance by procedures outlined in the accompanying Analysis Summary.¶
Unless alternate arrangements are made by you, the remainder of the submitted specimens will be discarded one (1) year from the date of this report; and generated data will be discarded five (5) years from the date the analyses were performed.¶
CERTIFICATION: Pursuant to New York Criminal Procedure Law Section 190.30(2), I certify that this report was made by me or is a true copy thereof for testing conducted at NMS Laboratories. I further certify that I am authorized by NMS Laboratories to make this certification.¶
Analysis Summary and Reporting Limits:¶
All of the following tests were performed for this case. For each test, the compounds listed were included in the scope. The Reporting Limit listed for each compound represents the lowest concentration of the compound that will be reported as being positive. If the compound is listed as None Detected, it is not present above the Reporting Limit. Please refer to the Positive Findings section of the report for those compounds that were identified as being present.¶
Acode 9560B - Synthetic Cannabinoids Screen (2019 Scope), Blood - Femoral Blood¶
-Analysis by High Performance Liquid Chromatography/Tandem Mass Spectrometry QTRAP (LC-MS/MS QTRAP) for:¶
| Compound | Rpt. Limit | Compound | Rpt. Limit |
|---|---|---|---|
| 4-cyano-CUMYL-BINACA | 0.10 ng/mL | AMB-FUBINACA | 1.0 ng/mL |
| 4-fluoro-MDMB-BINACA | 0.10 ng/mL | CUMYL-THPINACA | 0.10 ng/mL |
| 5-fluoro-EDMB-PINACA | 0.10 ng/mL | MDMB-CHMCZCA | 0.10 ng/mL |
| 5-fluoro-MDMB-PICA | 0.10 ng/mL | MDMB-CHMICA | 0.10 ng/mL |
| 5-fluoro-MDMB-PINACA / 5-fluoro-EMB-PINACA | 0.20 ng/mL | MDMB-CHMINAC | 0.10 ng/mL |
| MDMB-FUBICA | 0.10 ng/mL | ||
| 5-fluoro-MMB-PINACA | 0.050 ng/mL | MDMB-FUBINACA / EMB-FUBINACA | 0.10 ng/mL |
| 5-fluoro-NA-PIC | 0.10 ng/mL | MMB-CHMICA | 0.10 ng/mL |
| 5-fluoro-QU-PINAC | 0.10 ng/mL | MMB-CHMINAC | 0.20 ng/mL |
| ADAMANTYL-FUBINACA | 0.20 ng/mL | MMB-FUBINA | 1.0 ng/mL |
| ADMB-CHMINACA | 0.10 ng/mL | MMB-FUBINACA | 0.10 ng/mL |
| ADMB-FUBICA | 1.0 ng/mL | NA-FUBIC | 1.0 ng/mL |
| ADMB-FUBINACA | 1.0 ng/mL | NA-FUBIM | 0.20 ng/mL |
| AMB-CHMINACA | 1.0 ng/mL |
NMS v.18.0¶